Connection

Brent Egan to Antihypertensive Agents

This is a "connection" page, showing publications Brent Egan has written about Antihypertensive Agents.
Connection Strength

14.137
  1. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Press. 2022 12; 31(1):164-168.
    View in: PubMed
    Score: 0.625
  2. Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension. 2022 02; 79(2):338-348.
    View in: PubMed
    Score: 0.582
  3. Hypertension Control in the United States 2009 to 2018: Factors Underlying Falling Control Rates During 2015 to 2018 Across Age- and Race-Ethnicity Groups. Hypertension. 2021 09; 78(3):578-587.
    View in: PubMed
    Score: 0.565
  4. Antihypertensive Treatment in Elderly Frail Patients: Evidence From a Large Italian Database. Hypertension. 2020 08; 76(2):330-332.
    View in: PubMed
    Score: 0.530
  5. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019 06; 37(6):1148-1153.
    View in: PubMed
    Score: 0.491
  6. Adherence in Hypertension. Circ Res. 2019 03 29; 124(7):1124-1140.
    View in: PubMed
    Score: 0.485
  7. Improving Hypertension Control in Primary Care With the Measure Accurately, Act Rapidly, and Partner With Patients Protocol. Hypertension. 2018 12; 72(6):1320-1327.
    View in: PubMed
    Score: 0.474
  8. Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment. Hypertension. 2018 11; 72(5):1090-1092.
    View in: PubMed
    Score: 0.471
  9. Trends in Prehypertension and Hypertension Risk Factors in US Adults: 1999-2012. Hypertension. 2017 08; 70(2):275-284.
    View in: PubMed
    Score: 0.428
  10. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines. Hypertension. 2016 08; 68(2):318-23.
    View in: PubMed
    Score: 0.401
  11. Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension. J Clin Hypertens (Greenwich). 2016 08; 18(8):817-24.
    View in: PubMed
    Score: 0.390
  12. Treatment Resistant Hypertension. Ethn Dis. 2015 Nov 05; 25(4):495-8.
    View in: PubMed
    Score: 0.383
  13. Hypertension in african americans aged 60 to 79 years: statement from the international society of hypertension in blacks. J Clin Hypertens (Greenwich). 2015 Apr; 17(4):252-9.
    View in: PubMed
    Score: 0.366
  14. The growing gap in hypertension control between insured and uninsured adults: National Health and Nutrition Examination Survey 1988 to 2010. Hypertension. 2014 Nov; 64(5):997-1004.
    View in: PubMed
    Score: 0.353
  15. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. 2014 May 20; 129(20):2052-61.
    View in: PubMed
    Score: 0.344
  16. Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension. 2014 Mar; 63(3):e17-8.
    View in: PubMed
    Score: 0.341
  17. Pre-hypertension: rationale for pharmacotherapy. Curr Hypertens Rep. 2013 Dec; 15(6):669-75.
    View in: PubMed
    Score: 0.335
  18. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
    View in: PubMed
    Score: 0.328
  19. Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension. J Am Soc Hypertens. 2013 Jan-Feb; 7(1):95-101.
    View in: PubMed
    Score: 0.315
  20. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012 Jun; 59(6):1124-31.
    View in: PubMed
    Score: 0.301
  21. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011 Aug 30; 124(9):1046-58.
    View in: PubMed
    Score: 0.285
  22. Is blood pressure control to less than 140/less than 90 mmHg in 50% of all hypertensive patients as good as we can do in the USA: or is this as good as it gets? Curr Opin Cardiol. 2011 Jul; 26(4):300-7.
    View in: PubMed
    Score: 0.283
  23. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010 May 26; 303(20):2043-50.
    View in: PubMed
    Score: 0.263
  24. Antihypertensive medication prescribing patterns in a university teaching hospital. J Clin Hypertens (Greenwich). 2010 Apr; 12(4):246-52.
    View in: PubMed
    Score: 0.260
  25. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009 Jul; 22(7):792-801.
    View in: PubMed
    Score: 0.243
  26. Fixed-dose combinations and hypertension control in community-based practices: application of the "keep-it-simple" principle. Hypertension. 2009 Apr; 53(4):598-9.
    View in: PubMed
    Score: 0.241
  27. From TROPHY with pride. Am J Hypertens. 2007 Mar; 20(3):342-3; author reply 343-5.
    View in: PubMed
    Score: 0.210
  28. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006 Mar; 47(3):345-51.
    View in: PubMed
    Score: 0.194
  29. Challenges and risks in attaining the systolic blood pressure goal of <130 mm Hg in all diabetic patients. J Clin Hypertens (Greenwich). 2006 Jan; 8(1):50-2.
    View in: PubMed
    Score: 0.194
  30. Gender- and age-related differences in treatment and control of cardiovascular risk factors among high-risk patients with angina. J Clin Hypertens (Greenwich). 2005 Jul; 7(7):386-94.
    View in: PubMed
    Score: 0.187
  31. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. Curr Med Res Opin. 2004 Dec; 20(12):1909-17.
    View in: PubMed
    Score: 0.180
  32. A systematic approach to managing hypertension and the metabolic syndrome in primary care. South Med J. 2004 Oct; 97(10):932-8.
    View in: PubMed
    Score: 0.178
  33. An assessment of racial differences in clinical practices for hypertension at primary care sites for medically underserved patients. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):26-31; quiz 32-3.
    View in: PubMed
    Score: 0.169
  34. TIME to face the reality about evening dosing of antihypertensive drugs in hypertension. Blood Press. 2023 Dec; 32(1):1-3.
    View in: PubMed
    Score: 0.168
  35. Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research. Arch Intern Med. 2003 Mar 24; 163(6):681-7.
    View in: PubMed
    Score: 0.160
  36. Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults. JAMA Netw Open. 2022 12 01; 5(12):e2247787.
    View in: PubMed
    Score: 0.156
  37. Blood Pressure Control Among Non-Hispanic Black Adults Is Lower Than Non-Hispanic White Adults Despite Similar Treatment With Antihypertensive Medication: NHANES 2013-2018. Am J Hypertens. 2022 Jun 16; 35(6):514-525.
    View in: PubMed
    Score: 0.151
  38. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022 01; 79(1):e1-e14.
    View in: PubMed
    Score: 0.144
  39. Optimal Systolic Blood Pressure Target in Resistant Hypertension. Am J Med. 2019 07; 132(7):e623.
    View in: PubMed
    Score: 0.123
  40. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
    View in: PubMed
    Score: 0.118
  41. Insights on ?-blockers for the treatment of hypertension: A survey of health care practitioners. J Clin Hypertens (Greenwich). 2018 10; 20(10):1464-1472.
    View in: PubMed
    Score: 0.117
  42. Measure Accurately, Act Rapidly, and Partner With Patients (MAP) improves hypertension control in medically underserved patients: Care Coordination Institute and American Medical Association Hypertension Control Project Pilot Study results. J Clin Hypertens (Greenwich). 2018 01; 20(1):79-87.
    View in: PubMed
    Score: 0.111
  43. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2015 May; 8(3):235-43.
    View in: PubMed
    Score: 0.092
  44. Prehypertension--prevalence, health risks, and management strategies. Nat Rev Cardiol. 2015 May; 12(5):289-300.
    View in: PubMed
    Score: 0.091
  45. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014 Nov 04; 130(19):1692-9.
    View in: PubMed
    Score: 0.089
  46. Antihypertensive medication persistence 1-year post-stroke hospitalization. J Clin Hypertens (Greenwich). 2014 Dec; 16(12):869-74.
    View in: PubMed
    Score: 0.089
  47. The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child. Pediatr Nephrol. 2014 Aug; 29(8):1403-9.
    View in: PubMed
    Score: 0.085
  48. Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of Healthy People goals. J Clin Hypertens (Greenwich). 2013 Mar; 15(3):154-61.
    View in: PubMed
    Score: 0.079
  49. Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide? J Clin Hypertens (Greenwich). 2012 Jul; 14(7):415-21.
    View in: PubMed
    Score: 0.075
  50. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovasc Ther. 2010 Dec; 28(6):344-9.
    View in: PubMed
    Score: 0.068
  51. Prehypertension: an opportunity for a new public health paradigm. Cardiol Clin. 2010 Nov; 28(4):561-9.
    View in: PubMed
    Score: 0.068
  52. Prevalence and management of hypertension in the inpatient setting: a systematic review. J Hosp Med. 2011 Sep; 6(7):417-22.
    View in: PubMed
    Score: 0.066
  53. Prehypertension: risk stratification and management considerations. Curr Hypertens Rep. 2008 Oct; 10(5):359-66.
    View in: PubMed
    Score: 0.059
  54. Prehypertension: should we be treating with pharmacologic therapy? Ther Adv Cardiovasc Dis. 2008 Aug; 2(4):305-14.
    View in: PubMed
    Score: 0.058
  55. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008 Mar; 26(3):589-99.
    View in: PubMed
    Score: 0.056
  56. Dietary salt restriction and blood pressure in clinical trials. Curr Hypertens Rep. 2007 Aug; 9(4):314-9.
    View in: PubMed
    Score: 0.054
  57. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006 Apr 20; 354(16):1685-97.
    View in: PubMed
    Score: 0.049
  58. Ethnic differences in older americans: awareness, knowledge, and beliefs about hypertension. Am J Hypertens. 2005 Jul; 18(7):972-9.
    View in: PubMed
    Score: 0.047
  59. Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. Ethn Dis. 2005; 15(1):11-6.
    View in: PubMed
    Score: 0.045
  60. Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically under-served patients. Ethn Dis. 2005; 15(1):25-32.
    View in: PubMed
    Score: 0.045
  61. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. Am J Hypertens. 2004 Jun; 17(6):477-82.
    View in: PubMed
    Score: 0.043
  62. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
    View in: PubMed
    Score: 0.042
  63. Thirty years with LIFE-a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Press. 2022 12; 31(1):125-128.
    View in: PubMed
    Score: 0.039
  64. Associations between birth weight and antihypertensive medication in black and white medicaid recipients. Hypertension. 2002 Jan; 39(1):179-83.
    View in: PubMed
    Score: 0.037
  65. Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients. Am J Hypertens. 1997 Jan; 10(1):68-76.
    View in: PubMed
    Score: 0.026
  66. Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. J Clin Hypertens (Greenwich). 2011 Oct; 13(10):731-8.
    View in: PubMed
    Score: 0.018
  67. Measuring the impact of a continuing medical education program on patient blood pressure. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):517-22.
    View in: PubMed
    Score: 0.017
  68. Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension? Am J Cardiol. 2006 Oct 15; 98(8):1122.
    View in: PubMed
    Score: 0.013
  69. Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005 Jul; 18(7):980-5.
    View in: PubMed
    Score: 0.012
  70. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci. 2005 Jun; 329(6):292-305.
    View in: PubMed
    Score: 0.012
  71. Managing hypertension in the southeastern United States: applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Am J Med Sci. 1999 Dec; 318(6):357-64.
    View in: PubMed
    Score: 0.008
  72. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension. 1996 Jul; 28(1):120-6.
    View in: PubMed
    Score: 0.006
  73. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med. 1990 Feb 15; 112(4):270-7.
    View in: PubMed
    Score: 0.004
  74. Decreased venous distensibility and reduced renin responsiveness in hypertension. Hypertension. 1986 Jun; 8(6 Pt 2):II36-43.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.